Net profit of Venus Remedies rose 108.21% to Rs 6.85 crore in the quarter ended December 2023 as against Rs 3.29 crore during the previous quarter ended December 2022. Sales rose 22.69% to Rs 143.42 crore in the quarter ended December 2023 as against Rs 116.90 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales143.42116.90 23 OPM %8.396.93 - PBDT14.3211.76 22 PBT7.784.54 71 NP6.853.29 108 Powered by Capital Market - Live News

Venus Remedies will hold a meeting of the Board of Directors of the Company on 14 February 2024.Powered by Capital Market - Live News

Venus Remedies announced dual achievements in securing marketing authorisations for three variants of Docetaxel in Israel and Cytarabjne 100MG in Colombia. Powered by Capital Market - Live News

Venus Remedies achieved a significant milestone with the recent approval of marketing authorizations (MAs) for Enoxaparin 40 mg/0.4 ml and 60mg/0.6 ml in Azerbaijan, marking the first entry of these products into the country. Enoxaparin Sodium Injection, a low molecular weight heparin, effectively prevents blood clot enlargement and formation, addressing various medical condition. Powered by Capital Market - Live News

Net profit of Venus Remedies rose 86.49% to Rs 9.94 crore in the quarter ended September 2023 as against Rs 5.33 crore during the previous quarter ended September 2022. Sales rose 19.89% to Rs 167.72 crore in the quarter ended September 2023 as against Rs 139.89 crore during the previous quarter ended September 2022. ParticularsQuarter Ended�Sep. 2023Sep. 2022% Var. Sales167.72139.89 20 OPM %10.619.27 - PBDT20.7814.76 41 PBT14.345.77 149 NP9.945.33 86 Powered by Capital Market - Live News